Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-month phase 3 study comparing triple and dual inhaled therapies in adults with COPD and prior exacerbations
RBR-4sxpffPhase 3Completed
- Sponsor
- GSK
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluticasone, umeclidinium, vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Jun 2014; status: completed.
02
Drugs
fluticasoneumeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on RBR-4sxpff.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4sxpff.